Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

BCMA-Directed CAR T-Cell Therapy Makes Strong Entrance in Myeloma

March 1st 2019

B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities.

FDA Panel Votes Against Accelerated Approval of Selinexor for Myeloma

February 27th 2019

The FDA’s Oncologic Drugs Advisory Committee voted against accelerated approval of a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma, recommending delaying a decision on the drug until results are available from the pivotal phase III BOSTON trial.

Subcutaneous Daratumumab Succeeds in Phase III Myeloma Trial

February 26th 2019

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

Dr. Giralt on Allogeneic HCT in Multiple Myeloma

February 23rd 2019

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

Dr. Kumar on Utility of ASCT in Newly Diagnosed Multiple Myeloma

February 22nd 2019

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Expert Highlights Encouraging PFS Data With Maintenance Ixazomib in Multiple Myeloma

February 21st 2019

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

Dr. Holstein Discusses Role of Melflufen in Myeloma

February 20th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the role of melflufen in the treatment of patients with myeloma.

Treatment for Newly Diagnosed Patients Shifts Across Myeloma Spectrum

February 13th 2019

Jesus Berdeja, MD, discusses emerging standards of care in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma.

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

February 13th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the treatment of patients with newly diagnosed myeloma.

FDA Approves Split-Dosing Regimen of Daratumumab for Multiple Myeloma

February 13th 2019

The FDA has approved a split-dosing regimen of daratumumab for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.

New Paradigm Is Shaping Up for High-Risk Smoldering Myeloma

February 12th 2019

More than a dozen new treatments have boosted survival times for individuals with multiple myeloma. Now, researchers are beginning trials to investigate whether any of those treatments might improve on observation for patients with smoldering multiple myeloma who are at the highest risk of progression.

Dr. Cho Discusses Role of Bispecific Agents in Myeloma

February 12th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.

Dr. Holstein on Sequencing Strategies in Myeloma

February 8th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska, discusses considerations for determining on optimal treatment sequence for patients with myeloma.

FDA Schedules ODAC Meeting for Selinexor in Penta-Refractory Myeloma

February 8th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2019, to discuss a new drug application for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma.

Expert Highlights Ongoing Advances in Multiple Myeloma

February 7th 2019

Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

February 7th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Dr. Valent on Ongoing Research With Immunotherapy in Multiple Myeloma

February 6th 2019

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Isatuximab Triplet Improves PFS in Relapsed/Refractory Myeloma

February 5th 2019

Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Dr. Chari on Role of Immunotherapy in Myeloma

February 5th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.

Dr. Parekh on Potential Biomarker for Novel Drug in Myeloma

February 1st 2019

Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.